Biopharma Business

Tag "treatment"

Ketamine may help treat migraine pain unresponsive to other therapies

    Ketamine may help treat migraine pain unresponsive to other therapies

Ketamine, a medication commonly used for pain relief and increasingly used for depression, may help alleviate migraine pain in patients who have not been helped by other treatments. The study

Read Full Article

Treatment for hyperkalaemia receives European marketing approval recommendation

    Treatment for hyperkalaemia receives European marketing approval recommendation

Veltassa (patiromer), developed by Relypsa, has received a recommendation for marketing approval from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) for the

Read Full Article

EU expands use of Janssen’s Darzalex

EU regulators have expanded the scope of Janssen’s Darzalex to include patients with multiple myeloma who have received at least one prior therapy, when given in combination with lenalidomide and

Read Full Article

Allergan and Novartis Collaborate on Multi-Therapy Treatment for NASH

Allergan, a global biopharmaceutical company, announced that it has entered into a clinical trial agreement with Novartis to conduct a Phase 2b study, using Allergan’s cenicriviroc (CVC) and Novartis’ lead FXR

Read Full Article

BTG receives CE mark certification for radiopaque drug-eluting bead

BTG, a global specialist healthcare company, has received Class III CE Mark certification for DC Bead LUMI, the first commercially available radiopaque drug-eluting bead (DEB) in the EU which can

Read Full Article

Data Supports Advancement of Botox as Depression Treatment

Allergan plc, a global pharmaceutical company announced topline data from a phase II study with major depressive disorder (MDD). The study evaluated the efficacy, safety and tolerability of a single administration

Read Full Article

LSTM reports on a new way of screening potential treatments for TB

Scientists from LSTM’s Research Centre for Drugs and Diagnostics (RCDD) have described in a paper published today in Scientific Reports, a new way of screening potential treatments for Tuberculosis (TB)

Read Full Article

Pfizer’s Xeljanz Authorized for Marketing in the European Union

Xeljanz (tofacitinib citrate) receives marketing authorization in the European Union for the treatment of moderate to severe active rheumatoid arthritis (RA). Pfizer Inc. announced today that the European Commission (EC)

Read Full Article

EMA Recommends Approval of New Treatment for Brain Cancer

Apeiron Biologics has announced that the EMA’s CHMP has recommended the approval of APN311 for immunotherapy of high risk neuroblastoma. Apeiron Biologics is a Vienna-based biotech company developing immunological approaches

Read Full Article

Shire’s HAE drug Cinryze secures label extension in Europe

Shire has secured label expansion approval from the European Commission for its hereditary angioedema therapy Cinryze. The European Commission (EC) has approved the label extension application, granting three new indications

Read Full Article

Upcoming Events

  • No upcoming events
AEC v1.0.4

The Magazine

New Subscriber

Subscribe Here



Advertisements